Chembio Diagnostics and Stony Brook Medicine Collaborate to Identify Coronavirus Survivors
April 09 2020 - 3:05PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostic company focused on infectious diseases,
today announced its DPP COVID-19 serological point-of-care test for
the detection of IgM and IgG antibodies has been selected for use
in a Stony Brook Medicine effort to recruit patients who have
recovered from COVID-19 infection. The study is intended to
determine if convalescent blood plasma, the plasma from people who
have recovered from COVID-19, can help treat hospitalized patients
with active COVID-19 infection. In early April, Stony Brook
University Hospital received FDA approval to offer convalescent
blood plasma treatment to its patients through a randomized,
controlled study and is expected to enroll up to 500 patients from
the Long Island area. The Chembio DPP COVID-19 test is being used
to confirm that patients were infected with COVID-19 and now have
adequate levels of IgG antibodies to make them eligible to donate
convalescent plasma.
“We are fast-tracking this large-scale clinical trial, as every
second counts when seeking lifesaving treatment for these
critically ill patients,” said Elliott Bennett-Guerrero, MD,
Medical Director, Perioperative Quality and Patient Safety and
Professor and Vice Chair, Clinical Research and Innovation,
Department of Anesthesiology at Stony Brook Medicine. “The study
will assess the safety and efficacy of convalescent plasma versus
standard plasma in hospitalized adult patients with a confirmed
COVID-19 diagnosis.”
“Our collaboration with Stony Brook Medicine on this important
study represents the next step in our COVID-19 initiative, which
includes our earlier receipt of authorization to market and sell
the DPP COVID-19 IgM and IgG assay system in the United States
through the FDA notification process,” stated Javan Esfandiari,
Executive Vice President and Chief Science & Technology Officer
of Chembio. “We are pleased that our unique and proprietary DPP
technology, which can separately and simultaneously detect and
measure IgM and IgG antibodies specific to COVID-19, is the assay
of choice for Stony Brook Medicine.”
“Our patented technology uses one of two analyzers produced by
Chembio, known as MR1 and MR2, to read the test results for both
IgM and IgG antibodies from finger stick blood in 15 minutes and
gives a numerical result related to the amount of antibody in the
sample,” said Esfandiari. “This eliminates the individual
subjectivity of results and increases the sensitivity and
specificity of the test.”
To learn more please view the Stony Brook
Medicine announcement.
About Chembio DiagnosticsChembio is a leading
point-of-care diagnostics company focused on detecting and
diagnosing infectious diseases. The company’s patented DPP
technology platform, which uses a small drop of blood from the
fingertip, provides high-quality, cost-effective results in
approximately 15 minutes. Coupled with Chembio’s extensive
scientific expertise, its novel DPP technology offers broad market
applications beyond infectious disease, a number of which
applications are under active development with collaboration
partners. Chembio’s products are sold globally, directly and
through distributors, to hospitals and clinics, physician offices,
clinical laboratories, public health organizations, government
agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this
trademark appears in this release without ® symbols, but that
practice does not mean that Chembio will not assert, to the fullest
extent under applicable law, its rights to the trademark.
Contact: Philip TaylorGilmartin
Group(415) 937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2024 to May 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From May 2023 to May 2024